SG/PUT/NOVO-NORDISK B/850/0.1/20.09.24 Stock

DE000SU6X350

Market Closed - Bid/Ask 14:03:51 2024-07-03 EDT			After market 14:58:18
0.27 ^EUR	+22.73%		0.28	+3.70%

Current month	+28.57%
1 month	-37.21%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart SG/PUT/NOVO-NORDISK B/850/0.1/20.09.24

Latest news about NOVO NORDISK A/S

Sector Update: Health Care Stocks Fall in Afternoon Trading	12:52pm	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	12:08pm	MT
Top Midday Stories: Southwest Board Approves Shareholder Rights Plan; National Amusements Agrees to Preliminary Deal to Sell Paramount to Skydance; Ozempic, Wegovy Linked to Blinding Eye Condition, Study Says	11:59am	MT
Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows	11:51am	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-03	0.27	+22.73%
24-07-02	0.22	+15.79%
24-07-01	0.19	-9.52%
24-06-28	0.21	0.00%
24-06-27	0.21	0.00%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 02:03 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	NOVO NORDISK A/S
Issuer	Société Générale
WKN	SU6X35
ISIN	DE000SU6X350
Date issued	2024-01-12
Strike	850 kr
Maturity	2024-09-20 (79 Days)
Parity	10 : 1
Emission price	2.07 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	2.27 €
Lowest since issue	0.16 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	46.28x
Moneyness	0.8786
Difference Strike	-117.5 kr
Difference Strike %	-13.82%
Spread	0.02 €
Spread %	6.90%
Intrinsic value	0.000000
Present value	0.2900

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company